Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of Ankylosing Spondylitis (AS) fulfilling the modified New York criteria
Active axial disease at Screening and Baseline defined by a Bath Ankylosing
Spondylitis Disease Activity Index (BASDAI) score ≥ 4 and Total Back Pain ≥ 4
Failed prior treatment with at least 2 NSAIDs for at least 4 weeks each
Participant has never received a biologic therapy eg, tumor necrosis factor (TNF) antagonist or monoclonal antibody \[mAb\] against IL-17A (biologic naive main study), or have taken more than one biologic therapy (biologic-failure substudy) for the treatment of AS
You may not be if
Radiographic evidence of total ankylosis of the spine
Clinically significant back pain caused by diseases other than AS
Concurrent treatment or treatment within the 6 months prior to Baseline with cell depleting biologic agents
Participation in any study of an investigational drug, including those for COVID-19
History of malignancy
Oral corticosteroids (prednisone or equivalent) \> 10 mg/day systemically for ≥ 2 weeks prior to Baseline Visit
Clareo Health | A Study of CC-99677 in Participants With Active Ankylosing Spondylitis
